| 產(chǎn)品標題 |
產(chǎn)品貨號 |
產(chǎn)品規(guī)格 |
廠家 |
| ?Myeloperoxidase, Human Neutrophil | Athens Research & Technology | ?16-14-130000 | ?size | ?Athens Research |
| ?Myeloperoxidase Enzyme Immunoassay Kit | Athens Research & Technology | ?K060-H1 | ?size | ?Athens Research |
| ?ML 130 | NOD1 inhibitor | Noditinib | ML130 | ML-130 | CAS [799264-47-4] | Axon 1888 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 1888
CAS [799264-47-4]
MF C14H13N3O2SMW 287.34
Purity:
99%
Soluble in DMSO
Description
Potent and selective inhibitor of NOD1.
KEYWORDS:?ML 130 | supplier | NOD1 inhibitor | Noditinib | ML130 | ML-130 | CAS [799264-47-4] | NF-κB Pathway | NOD1 | NLR | NACHT | leucine rich repeat domain containing proteins | innate | immunity | inflammation | apoptosis | | ?axonmedchem |
| ?AX-024 hydrochloride | T cell receptor inhibitor | AX024 hydrochloride | AX 024 hydrochloride | AX-024 | AX024 | AX 024 | CAS [1704801-24-0] - [1370544-73-2] | Axon 2692 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 2692
CAS [1704801-24-0]
MF C21H22FNO2.HClMW 375.86
Purity:
99%
Soluble in water and DMSO
Description
First-in-class inhibitor of T cell receptor (TCR); AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). By modulating TCR signaling, the inhibitor prevented the development of psoriasis and asthma and, furthermore, exerted a long-lasting therapeutic effect in a model of autoimmune encephalomyelitis.
KEYWORDS: AX-024 hydrochloride | supplier | T cell receptor inhibitor | AX024 hydrochloride | AX 024 hydrochloride | AX-024 | AX024 | AX 024 | Ax24 | CAS [1704801-24-0] | [1370544-73-2] | Antigen | T cell | Inhibitor | Receptors | TCR | Autoimmune | Nck | TCR-Nck | Psoriasis | Asthma | Encephalomyelitis | | ?axonmedchem |
| ?Temozolomide | DNA methylating agent | TMZ | NSC 362856 | SCH 52365 | CCRG 81045 | 97716-75-1 | Temodal | NSC362856 | SCH52365 | CCRG81045 | CAS [85622-93-1] | Axon 2326 | Axon Ligand? with >100% purity available from stock from supplier Axon Medchem | ?Axon 2326
CAS [85622-93-1]
MF C6H6N6O2MW 194.15
Purity:
100%
Soluble in 0.1N HCl(aq) and DMSO
Description
Chemotherapeutic apoptosis inducer. An orally active alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). Temozolomide has demonstrated efficacy in the treatment of a variety of solid tumors, primary malignant brain tumors and metastatic melanoma (IC50 value 5 μM for cytotoxicity against mouse TLX5 lymphoma cells).The primary cytotoxic lesion, O6-methylguanine (O6-MeG) can be removed by methylguanine methyltransferase (MGMT; direct repair) in tumours expressing this protein, or tolerated in mismatch repair-deficient (MMR-) tumours.
References
Certificates
Categories
Extra info
J. Zhang et al. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012, 5, 102-114.
?
H.S. Friedman et al. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 2000, 6, 2585-2597.
Certificate of Analysis
Material Safety Data Sheet
Apoptosis
Cell Cycle Regulation
Cell Signaling & Oncology
DNA-damage Response
DNA
DNA methylating agent; apoptosis inducer
Chemical name
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Parent CAS No.
[85622-93-1]
Order
Size
Unit Price
Stock
10 mg
€50.00
In Stock | | ?axonmedchem |
| ?RTA 408 | NRF2 acitivator | Omaveloxolone | RTA408 | CAS [1474034-05-3] | Axon 2497 | Axon Ligand? with >98% purity available from stock from supplier Axon Medchem | ?Axon 2497
CAS [1474034-05-3]
MF C33H44F2N2O3MW 554.71
Purity:
98%
Optical purity:
Optically pure
Soluble in DMSO
Description
Synthetic triterpenoid that potently activates the antioxidative transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) and inhibits the proinflammatory transcription factor NF-κB at low concentrations. RTA 408 dose-dependently reduced NO concentrations (IC50 value 4.4 Nm). At higher concentrations, RTA 408 inhibited tumor cell growth (GI50 value 260 nM) and increased caspase activity in tumor cell lines and is a highly effective mitigator of steady state hematopoiesis.
KEYWORDS: RTA 408 | NRF2 acitivator | Axon 2497 | Omaveloxolone | RTA408 | CAS [1474034-05-3] | DNA-RNA | NRF | Activator | Transcription Factor | NF-E2L2 | ROS | NO | nuclear factor erythroid 2-related factor 2 | JNK | NF-κB | inflammatory | radiation | mitigator | hematopoiesis | | ?axonmedchem |
| ?NEO 212 | DNA alkylating agent | TMZ-POH | TMZPOH | CAS [1361198-79-9] | Axon 2327 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 2327
CAS [1361198-79-9]
MF C17H20N6O4MW 372.38
Purity:
99%
Optical purity:
Optically pure
Soluble in DMSO
Description
Novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo (IC50 values 5-50 μM for cytotoxicity on glioma cell lines). NEO 212 causes DNA damage and cell death much more efficiently than TMZ, because linkage with POH increased its biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.NEO212 is a conjugate of temozolomide (TMZ, Axon 2326) with the natural product perillyl alcohol (POH) and circumvents TMZ-resistance in multiple cancer cell lines and gliomas.
References
Certificates
Categories
Extra info
T.C. Chen et al. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol. Cancer Ther. 2014, 13, 1181-1193.
?
H.Y. Cho et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer Ther. 2014, 13, 2004-2017.
Certificate of Analysis
Material Safety Data Sheet
Apoptosis
Cell Cycle Regulation
Cell Signaling & Oncology
DNA-damage Response
DNA
DNA alkylating agent; chemotherapeutic
Chemical name
(S)-(4-(Prop-1-en-2-yl)cyclohex-1-enyl)methyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonylcarbamate
Parent CAS No.
[1361198-79-9]
Order
Size
Unit Price
Stock
5 mg
€110.00
In Stock | | ?axonmedchem |
| ?ML334 | NRF2 acitivator | LH601A | ML-334 | LH-601A | CAS [1432500-66-7] | Axon 2641 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 2641
CAS [1432500-66-7]
MF C26H26N2O5MW 446.50
Purity:
99%
Optical purity:
Optically pure
Soluble in DMSO
Description
Activator of NRF2 signaling by inhibition of Keap1-NRF2 protein-protein interaction (PPI; IC50 value 1.6 - 2.3 μM in a fluorescence polarisation assay using Keap1 Kelch domain/NRF2-ETGE peptide; Kd value 1 μM to Keap1 Kelch domain). ML 334 stimulates NRF2 expression and nuclear translocation, and induces antioxidant response elements (ARE) and transcription of HO-1 and TRX1 proteins.
KEYWORDS:?ML 334 | supplier | NRF2 acitivator | LH 601A | ML334 | LH601A | ML-334 | LH-601A | CAS [1432500-66-7] | DNA-RNA | NRF | Keap | Transcription Factor | Keap1-NRF2 | protein-protein interaction | Neurodegenerative | PPI | Kelch domain | expression | translocation | antioxidant response elements | HO-1 | TRX1 | | ?axonmedchem |
| ?ML385 | NRF2 inhibitor | ML-385 | ML 385 | CAS [846557-71-9] | Axon 2671 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 2671
CAS [846557-71-9]
MF C29H25N3O4SMW 511.59
Purity:
99%
Soluble in DMSO
Description
ML385 is an inhibitor of nuclear factor erythroid 2-related factor 2 (NRF2) (IC50 value 1.9 μM), blocks NRF2 transcriptional activity, and enhances the efficacy of carboplatin and other chemotherapeutic drugs in lung cancer cells (NSCLC). Specifically, ML385 binds to Neh1, the Cap ‘N’ Collar Basic Leucine Zipper (CNC-bZIP) domain of NRF2, and interferes with the binding of the V-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homologue G (MAFG)-NRF2 protein complex to regulatory DNA binding sequences. ML385 shows specificity and selectivity for NSCLC cells with KEAP1 mutation.
KEYWORDS: ML385 | supplier | NRF2 inhibitor | ML-385 | ML 385 | CAS [846557-71-9] | DNA-RNA | NRF | Keap | Inhibitor | Transcription Factors | NSCLC | KEAP1 | NRF2 | CNC-bZIP | MAFG | non-small cell lung cancer | | ?axonmedchem |
| ?2,5-Dimethylcelecoxib | Apoptosis inducer | DMC | CAS [457639-26-8] | Axon 2496 | Axon Ligand? with >100% purity available from stock from supplier Axon Medchem | ?Axon 2496
CAS [457639-26-8]
MF C18H16F3N3O2SMW 395.40
Purity:
100%
Soluble in DMSO
Description
Celecoxib analog that lacks COX-2 inhibitory activity but exhibits anti-tumor properties; DMC reduced growth and initiated apoptotic cell death in several MM cell lines. Mechanistically, DMC down-regulates critical components of the cell-cycle machinery (cyclins A and B); blocks the activity of important mitogenic and survival pathways (MEK, NF-κB, STAT3, survivin); and leads to increased caspase activity. Moreover, DMC quite potently mimics the ability of celecoxib to stimulate the endoplasmic reticulum stress response (ESR) and subsequent cell death .
References
Certificates
Categories
Extra info
A. Kardosh et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood. 2005 Dec 15;106(13):4330-8.
?
A. Kardosh et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther. 2005 May;4(5):571-82.
?
P. Pyrko et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther. 2007 Apr;6(4):1262-75.
Certificate of Analysis
Material Safety Data Sheet
Angiogenesis
Cardiovascular
Cell Cycle Regulation
Cell Signaling & Oncology
NF-κB
MAPK
JAK-STAT
Unclassified
Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity
Chemical name
4-(5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Parent CAS No.
[457639-26-8]
Order
Size
Unit Price
Stock
10 mg
€75.00
In Stock | | ?axonmedchem |
| ?JSH 23 | NF-κB inhibitor | JSH23 | CAS [749886-87-1] | Axon 2349 | Axon Ligand? with >99% purity available from stock from supplier Axon Medchem | ?Axon 2349
CAS [749886-87-1]
MF C16H20N2MW 240.34
Purity:
99%
Soluble in 0.1N HCl(aq) and DMSO
Description
Inhibitor of NF-κB transcription and nuclear translocation of p65 (IC50 value 7.1 μM for inhibition of LPS-induced NF-κB transcriptional activity) without affecting IκBα degradation, which is a very rare mode of action. JSH 23 inhibited not only LPS-induced expressions of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and inducible nitric oxide synthase and cyclooxygenase-2 but also LPS-induced apoptosis of the RAW 264.7 cells. JSF 23 also inhibits NO production in LPS-stimulated macrophages RAW 264.7 (IC50 value 14.4 μM).
KEYWORDS:?JSH 23 | supplier | NF-κB inhibitor | JSH23 | CAS [749886-87-1] | NF-κB | Inhibitor | p65 | IκB | inflammation | transcription factor | Pro-inflammatory | cytokine | LPS | IKK | RAW 264.7 | COX-2 | | ?axonmedchem |
| title | productcode | size | brand |
| ?Myeloperoxidase, Human Neutrophil | Athens Research & Technology | ?16-14-130000 | ?size | ?Athens Research |
| ?Myeloperoxidase Enzyme Immunoassay Kit | Athens Research & Technology | ?K060-H1 | ?size | ?Athens Research |
| ?Haptoglobin, Human Plasma, Mixed Type | Athens Research & Technology | ?16-16-080116 | ?size | ?Athens Research |
| ?Apolipoprotein AI, Human Plasma | Athens Research & Technology | ?16-16-120101 | ?size | ?Athens Research |
| ?Vitronectin, Human Plasma | Athens Research & Technology | ?16-16-220920 | ?size | ?Athens Research |
| ?Laccase (LAC), Recombinant Microbial (Swissaustral USA) | Athens Research & Technology | ?16-13-120100 | ?size | ?Athens Research |
| ?Myeloperoxidase Enzyme Immunoassay Kit | Athens Research & Technology | ?K060-H1 | ?size | ?Athens Research |
| ?Anti-Thrombospondin Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-20-201319 | ?size | ?Athens Research |
| ?Anti-Trypsin Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-19-032000 | ?size | ?Athens Research |
| ?Anti-Myeloperoxidase Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-14-130000 | ?size | ?Athens Research |
| ?Anti-Haptoglobin Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-16-080116 | ?size | ?Athens Research |
| ?Anti-Fibrinogen Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-16-060902 | ?size | ?Athens Research |
| ?Anti-Elastase Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-14-051200 | ?size | ?Athens Research |
| ?Anti-Cathepsin L Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-12-030112 | ?size | ?Athens Research |
| ?Anti-Cathepsin D Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-12-030104 | ?size | ?Athens Research |
| ?Anti-Cathepsin H Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-12-030108 | ?size | ?Athens Research |
| ?Anti-Cathepsin B Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-12-030102 | ?size | ?Athens Research |
| ?Anti-Catalase Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-05-030000 | ?size | ?Athens Research |
| ?Anti-Azurocidin Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-14-012621 | ?size | ?Athens Research |
| ?Anti-Apolipoprotein CII Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-16-120302 | ?size | ?Athens Research |
| ?Anti-Apolipoprotein AI Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-16-120101 | ?size | ?Athens Research |
| ?Anti-Amylase Polyclonal Ab produced in rabbit | Athens Research & Technology | ?01-19-010000 | ?size | ?Athens Research |
| ?Glutamate Dehydrogenase, Recombinant Microbial (Swissaustral USA) | Athens Research & Technology | ?16-13-070408 | ?size | ?Athens Research |
| ?Catalase, Recombinant Microbial (Swissaustral USA) | Athens Research & Technology | ?16-13-030000 | ?size | ?Athens Research |
| ?Trypsin, Human Pancreas | Athens Research & Technology | ?16-19-032000 | ?size | ?Athens Research |
| ?Transferrin, Human Plasma, Bio Processing Grade | Athens Research & Technology | ?16-16-032001-BPG | ?size | ?Athens Research |
| ?Transferrin, Rat Plasma | Athens Research & Technology | ?16-16-032001-rat | ?size | ?Athens Research |
| ?Transferrin, Human Plasma (SIDERO), Partially Iron Saturated, Tissue Culture Grade | Athens Research & Technology | ?16-16-S32001-LEL | ?size | ?Athens Research |
| ?Transferrin (HOLO), Human Plasma, Tissue Culture Grade | Athens Research & Technology | ?16-16-032001-LEL | ?size | ?Athens Research |
| ?Transferrin (HOLO), Human Plasma | Athens Research & Technology | ?16-16-032001 | ?size | ?Athens Research |
| ?Transferrin, Cynomolgus Monkey Plasma | Athens Research & Technology | ?16-16-032001-CM | ?size | ?Athens Research |
| ?Thrombospondin, Human Platelet | Athens Research & Technology | ?16-20-201319 | ?size | ?Athens Research |
| ?Superoxide Dismutase, Human Erythrocyte | Athens Research & Technology | ?16-05-191504 | ?size | ?Athens Research |
| ?S-100αα Protein, Bovine Brain | Athens Research & Technology | ?16-BR-190801-bovine | ?size | ?Athens Research |
| ?S-100b Protein, Bovine Brain | Athens Research & Technology | ?16-BR-190802-bovine | ?size | ?Athens Research |
| ?Secretory Immunoglobulin A, Human Colostrum (SigA) | Athens Research & Technology | ?16-13-090701 | ?size | ?Athens Research |
| ?S-100 Protein, Bovine Brain | Athens Research & Technology | ?16-BR-190816-bovine | | ?Athens Research |
| ?Rheumatoid Factor IgM, Human Plasma | Athens Research & Technology | ?16-16-180603 | ?size | ?Athens Research |